Differential neutrophil activation in viral infections: Enhanced TLR-7/8-mediated CXCL8 release in asthma

Tang, Francesca S.M.; Van Ly, David; Spann, Kirsten; Reading, Patrick C.; Burgess, Janette K.; Hartl, Dominik; Baines, Katherine J.; Oliver, Brian G.

Published in:
Respirology

DOI:
10.1111/resp.12657

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Tang, F. S. M., Van Ly, D., Spann, K., Reading, P. C., Burgess, J. K., Hartl, D., Baines, K. J., & Oliver, B. G. (2016). Differential neutrophil activation in viral infections: Enhanced TLR-7/8-mediated CXCL8 release in asthma. Respirology, 21(1), 172-179. https://doi.org/10.1111/resp.12657

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Differential neutrophil activation in viral infections: Enhanced TLR-7/8-mediated CXCL8 release in asthma

FRANCESCA S.M. TANG,1,2 DAVID VAN LY,1,3 KIRSTEN SPANN,4 PATRICK C. READING,5 JANETTE K. BURGESS,1,2 DOMINIK HARTL,6 KATHERINE J. BAINES7 AND BRIAN G. OLIVER1,8

1Woolcock Institute of Medical Research, The University of Sydney, 2Discipline of Pharmacology, School of Medical Sciences, Faculty of Medicine, The University of Sydney, 3Genome Integrity Group, The Children’s Medical Research Institute, Sydney, New South Wales, 4School of Biomedical Science, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, 5WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, 6Priority Research Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, 8School of Medical and Molecular Biosciences, University of Technology Sydney, Sydney, New South Wales, Australia, and 7Department of Pediatrics I, University of Tübingen, Tübingen, Germany

ABSTRACT

Background and objective: Respiratory viral infections are a major cause of asthma exacerbations. Neutrophils accumulate in the airways and the mechanisms that link neutrophilic inflammation, viral infections and exacerbations are unclear. This study aims to investigate anti-viral responses in neutrophils from patients with and without asthma and to investigate if neutrophils can be directly activated by respiratory viruses.

Methods: Neutrophils from peripheral blood from asthmatic and non-asthmatic individuals were isolated and stimulated with lipopolysaccharide (LPS) (1 µg/mL), f-met-leu-phe (fMLP) (100 nM), imiquimod (3 µg/mL), R848 (1.5 µg/mL), poly I:C (10 µg/mL), RV16 (multiplicity of infection (MOI)1), respiratory syncytial virus (RSV) (MOI1) or influenza virus (MOI1). Cell-free supernatants were collected after 1 h of neutrophil activation in innate immune cells.

Results: LPS, fMLP, imiquimod and R848 stimulated the release of CXCL8, NE and MMP-9 whereas poly I:C selectively induced CXCL8 release only. R848-induced CXCL8 release was enhanced in neutrophils from asthmatics compared with non-asthmatic cells (P < 0.01). RSV triggered the release of CXCL8 and NE from neutrophils, whereas RV16 or influenza had no effect.

Conclusion: Neutrophils release CXCL8, NE and MMP-9 in response to viral surrogates with

SUMMARY AT A GLANCE

We aimed to investigate and compare neutrophil responses to bacterial compounds and viral mimetics as well as compare responses between people with and without asthma. We also investigated neutrophil responses to live respiratory viruses. Here we provide a novel comprehensive comparison showing differential and specific activation in innate immune cells.

R848-induced CXCL8 release being specifically enhanced in asthmatic neutrophils. Toll-like receptor (TLR7/8) dysregulation may play a role in neutrophilic inflammation in viral-induced exacerbations.

Key words: asthma, innate immune responses, neutrophils, respiratory viruses, rhinovirus.

Abbreviations: ANOVA, analysis of variance; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; FEV1, forced expiratory volume in 1 s; fMLP, f-met-leu-phe; FVC, forced vital capacity; ICS, inhaled corticosteroid; IL, interleukin; LPS, lipopolysaccharide; MDA-5, melanoma differentiation-associated protein 5; MMP, matrix metalloproteinase; MOI, multiplicity of infection; NE, neutrophil elastase; PAMPs, pathogen-associated molecular patterns; RSV, respiratory syncytial virus; RV, rhinovirus; TLR, toll-like receptor.

INTRODUCTION

Neutrophilic asthma is a distinct asthmatic phenotype with poor therapeutic response and a lack of mechanistic insights.1 In these patients, neutrophil numbers and their secretory products, such as CXCL8, neutrophil elastase (NE) and matrix metalloproteinase (MMP)-9, are elevated in the airways, particularly during exacerbation. These levels also correlate with greater severity of asthma symptoms.2,3
Respiratory viral infections are a major cause of asthma exacerbations with rhinovirus (RV) accounting for up to 80% of all exacerbations. Airway neutrophilia can also occur transiently in response to viral infections. Neutrophils appear to be implicated both in asthma and during infections; however, the immune responses that regulate virus-induced exacerbations and, in particular, neutrophilic inflammation remain poorly defined.

Neutrophils contain a range of receptors that recognize pathogen-associated molecular patterns (PAMPs) present on bacteria, fungi and viruses. The majority of respiratory viruses are RNA viruses that can be detected by toll-like receptors (TLRs) 3, 7 and 8. Studies have already described the expression of TLR7 and 8 in neutrophils with conflicting evidence for TLR3. It has been reported that asthmatic epithelial cells produce a deficient immune response in the context of a viral infection. Furthermore, airway neutrophils from asthmatics produce less inflammatory cytokines in response to lipopolysaccharide (LPS). It is currently unknown if there is dysfunction in the anti-viral capacity of asthmatic neutrophils and whether this may contribute to viral-induced exacerbations.

We hypothesize that neutrophils in asthmatic patients have a deficient anti-viral response that may contribute to the pathogenesis of viral-induced exacerbations. In this study, we aimed to determine whether neutrophils from asthmatics have an altered anti-viral response and whether neutrophils can detect and respond to replication competent (live) RV, respiratory syncytial virus (RSV) and influenza virus infections.

METHODS

Patient recruitment
The project protocols were approved by the Human Research Ethics Committee, The University of Sydney, prior to commencement. Patients were recruited by ethically approved flyers placed around the University of Sydney campuses and were included in the study if they were over the age of 18 and fluent in English. Exclusion criteria included pregnancy, fainting during venipuncture, having a blood-borne infection or condition, or if asthmatics were exacerbating. All patients provided written informed consent and were asked to complete a standardized questionnaire regarding age, sex, asthma symptoms and asthma medication use. Patients also completed baseline spirometry for forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) (Table 1).

Neutrophil isolation
Neutrophils were isolated from peripheral blood collected from asthmatic and non-asthmatic volunteers by a modified standard protocol with CD16-positive selection. Further details are provided in Supplementary Appendix S1. HE stain was used to assess purity of neutrophils that was typically 99%. The main contaminating cell was eosinophils.

| Table 1 Patient characteristics | Non-asthmatic | Asthmatic |
|--------------------------------|--------------|-----------|
| n                              | 28           | 19        |
| Age years, mean (± SEM)         | 26.11 (1.34) | 34.89 (4.45) |
| Gender (M/F)                    | 15/13        | 9/10      |
| FEV1, % pred. (± SEM)           | 96.14 (2.13) | 77.42*** (4.33) |
| FEV1/FVC % pred. (± SEM)        | 94.5 (3.6)   | 87.95* (3.04) |
| Short acting β2 agonist use     |              |           |
| (daily/weekly/less than weekly) | 7/4/8        |           |
|ICS use (daily/weekly/less than weekly) | 10/3/6       |           |

RV16, RSV and influenza virus
RV16 was generously donated by Professor Sebastian Johnston, Imperial College, London. RV16 was grown in HeLa cells by standard procedures and infectivity titre determined by a titration assay as described. RSV (A2) was grown in Hep2a cells by standard procedures, and infectivity titre was determined by a plaque assay on Hep2a cell monolayers as described. Influenza A virus strain A/California/7/2009 (A(H1N1)pdm09) from the WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia, was grown in 10-day embryonated hen’s eggs by standard procedures and infectivity titre was determined by plaque assay on MDCK cell monolayers as described.

Stimulation of neutrophils with TLR agonists and respiratory viruses
Neutrophils were resuspended in 1% foetal bovine serum (Glendralach Biologicals, Melbourne, Victoria, Australia), 1% 1 M N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulphonic acid] (Life Technologies, Mulgrave, Victoria, Australia) 1% penicillin/streptomycin RPMI 1640 (Life Technologies) at 10^6 cells/mL. Cells were unstimulated (negative control) or stimulated with EC_{50} concentrations of each TLR agonist based on dose–response curves generated for CXCL8 release (data not shown): 1 µg/mL LPS (Sigma Aldrich, Castle Hill, New South Wales, Australia), 3 µg/mL imiquimod (Inivogen, San Diego, CA, USA), 1.5 µg/mL R848 (Inivogen), 10 µg/mL poly I:C (Sigma Aldrich), except f-met-leu-phe (IMLP; Sigma Aldrich) (100 nM), which was based on previous reports. Neutrophils were also stimulated with RV16 at a multiplicity of infection (MOI) of 1 infectious particle per cell as previously published. This remained consistent with RSV (MOI) and influenza virus (MOI). Cells were incubated at 37°C with 5% CO₂ for 1 h NE and MMP-9 measurements, or 24 h for CXCL8 measurements. Cell-free supernatant and neutrophil cell pellets were collected and stored at −80°C for analysis.
Table 2  CXCL8, NE and MMP-9 release from neutrophils stimulated with bacterial compounds and viral mimics

|                | CXCL8 (pg/mL) | NE (ng/mL) | MMP-9 (fold change of control) |
|----------------|--------------|------------|-------------------------------|
| Control        | 173.3 (± 22.72) | 46.56 (± 5.98) | 1                             |
| DMSO           | 241.6 (± 59.64) | 49.92 (± 7)   | 1.23 (± 0.08)                 |
| LPS (1 μg/mL)  | 11 080 (± 1782)** | 60.76 (± 7.08)* | 2.53 (± 0.28)**               |
| fMLP (100 nM)  | 1 103 (± 258.4)*** | 91.23 (± 6.54)*** | 3.44 (± 0.5)****              |
| Imiquimod (3 μg/mL) | 1 630 (± 275)*** | 69.92 (± 7.66)** | 2.65 (± 0.42)***              |
| R848 (1.5 μg/mL) | 8 898 (± 1616)*** | 63.6 (± 6)* | 3.76 (± 0.88)***              |
| Poly I:C (10 μg/mL) | 992.6 (± 271.5)*** | 52.1 (± 8.36) | 1.29 (± 0.12)                |

CXCL8, NE and MMP-9 release from pooled data from asthmatic and non-asthmatic neutrophils. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control conditions.

DMSO, dimethyl sulfoxide; fMLP, f-met-leu-phe; LPS, lipopolysaccharide; MMP-9, matrix metalloproteinase-9; NE, neutrophil elastase.

**CXCL8 enzyme-linked immunosorbent assay (ELISA)**

CXCL8 production was measured using a sandwich ELISA in duplicate. Specific ELISA kits from R&D Systems (Minneapolis, MN, USA) were used according to the manufacturer’s instructions. Detection limit was 15.6 pg/mL.

**NE activity assay**

NE activity was measured in duplicate using a fluorescent assay from Cayman Chemicals (Ann Arbor, MI, USA) according to the manufacturer’s instructions. Fluorescence readings from samples were compared with a standard curve of known concentrations of NE to determine the concentration. Detection limit was 3.1 ng/mL.

**MMP-9 zymography**

A bicinchoninic acid assay (Sigma Aldrich) was run for all samples according to the manufacturer’s instructions to obtain the total protein concentration. Zymography was carried out according to previously published methods. Further details are provided in Supplementary Appendix S1.

**Statistical analysis**

Data are represented as the mean ± standard error of the mean. Data sets with greater than 10 patients were deemed to have a normal distribution if it passed one of the three normality tests provided (Kolmogorov–Smirnov, D’Agostino and Pearson and Shapiro–Wilk normality tests; GraphPad Prism 5, La Jolla, CA, USA). Non-parametric data were log_{10} transformed and normality tested again. A paired t-test or one-way analysis of variance (ANOVA) with Bonferroni post-test was performed if the data followed a normal distribution, or a Wilcoxon matched t-test or Friedman test with Dunn’s multiple comparison test if data were non-parametric. Two-way ANOVA was performed for groups comparing asthmatic cells versus non-asthmatic cells. Significant changes were identified where P < 0.05.

**RESULTS**

**Patient characteristics**

The mean age of the non-asthmatic group was 26.11 years, whereas the asthmatic patients were slightly older (34.89 years). There were approximately equal numbers of males and females in each group. The asthmatics had a significantly lower % predicted FEV1 and % predicted FEV1/FVC compared with the non-asthmatic group and all were on a short-acting β2 agonist and an inhaled corticosteroid (ICS) (Table 1).

**Bacterial compounds and viral mimics trigger the release of CXCL8 from neutrophils**

We first wanted to confirm that neutrophils were able to be activated by TLR agonists that mimic viral infections and compare their response to known bacterial activators. The bacterial compounds, LPS and fMLP, induced CXCL8 with LPS inducing approximately 10-fold more CXCL8 than fMLP. The viral surrogates (imiquimod, R848 and poly I:C) also induced release of CXCL8 from neutrophils with the TLR7/8 agonist, R848, inducing the greatest levels that was of similar magnitude to LPS stimulation (Table 2). Interleukin (IL)-6 was not detectable after stimulation with any of the TLR agonists and, therefore, this cytokine was not quantified in subsequent experiments.

**Bacterial compounds and viral mimics trigger degranulation of neutrophils**

NE is the most prominent azurophilic granule product and is a measure of degranulation. fMLP and LPS increased NE release as did imiquimod and R848; however, poly I:C did not (Table 2).

MMP-9 is predominately found in neutrophil gelatinase granules and zymography was used to detect its release by means of activity (gelatin digestion). fMLP was a potent inducer of MMP-9 release causing approximately 3.5-fold increase in release compared with basal levels. LPS also induced MMP-9 but to a lesser degree. R848 was also a potent inducer of MMP-9 release with similar levels to fMLP while imiquimod-induced release was similar to LPS. In contrast, poly I:C did not induce MMP-9 release from neutrophils (Table 2).

**Neutrophils derived from asthmatics had enhanced R848-induced CXCL8 release**

We next were interested in whether neutrophils from people with asthma had inherently altered immune responses to viral mimics that could contribute to the
inflammatory milieu in the airways of these patients. We found that upon R848 stimulation (TLR7/8 agonist) neutrophils from asthmatics produced nearly twice as much CXCL8 as non-asthmatic neutrophils (Fig. 1b). However, there were no differences found between these groups when we looked at LPS- and fMLP-induced CXCL8 (Fig. 1a), NE release (Fig. 2a,b) or MMP-9 release (Fig. 3a,b).

Respiratory viruses differentially modulate neutrophil responses

As neutrophils released CXCL8, NE and MMP-9 in response to TLR agonists, we next determined the ability of infectious RV16 to induce these mediators from neutrophils. RV was chosen due to the high prevalence in the community and did not induce CXCL8, NE or MMP-9 release from neutrophils (Fig. 4a–c).

Influenza virus also has been detected in the airways of exacerbating asthmatics. Neutrophils stimulated with influenza virus also did not induce CXCL8, NE or MMP-9 (Fig. 5a–c).

We next investigated RSV as it is another common respiratory virus detected in the airways of exacerbating asthmatics, particularly in children. Unlike RV16 or influenza virus, RSV did induce CXCL8 (Fig. 6a) and NE (Fig. 6b); however, MMP-9 was not detected (Fig. 6c).

We also assessed viral interaction with neutrophils by detecting viral RNA in a subset of neutrophil cell pellets by reverse transcription polymerase chain reaction. We found that RV and RSV RNA were present in neutrophil cell pellets 24 h post-stimulation (Supplementary Figs S1 & S2). We were unable to detect influenza in our samples due to technical limitations.

DISCUSSION

This is the first study to comprehensively explore classical neutrophil functions utilized against bacteria in the context of viral infections. We compared neutrophil responses against simulated bacterial and viral infections, immune responses between asthmatic and non-asthmatic neutrophils and finally neutrophil responses between viral surrogates and live viruses. We found that neutrophils were able to respond, by means of CXCL8, NE and MMP-9 release, to a variety of TLR agonists that mimic viral infections.

Notably, asthmatic neutrophils produced significantly more CXCL8 in response to R848 that has not been previously demonstrated. R848 non-specifically binds to both TLR7 and 8 and as no difference was observed with the specific TLR7 agonist, imiquimod, it can be concluded that the observation is due to dysregulated TLR8 activation. This may have substantial implications as the expression of TLR8 in neutrophils is the greatest of the three TLRs investigated, and TLR8 is not expressed in eosinophils. Oxidative stress has been confirmed in asthmatic airways by analysis of bronchial alveolar lavage fluid.
and has been reported to augment TLR8 activation,¹⁹ which may potentially exacerbate neutrophilic inflammation. Genetic studies have also linked TLR7 and TLR8 polymorphisms to increased risk of asthma.²⁰

Interestingly, out of the three respiratory viruses tested, only RSV was able to activate neutrophils even though TLR ligands could cause release of all mediators investigated. Neutrophils, in principle, are unable to differentiate between different types of viruses; rather they recognize PAMPs via TLRs. The majority of respiratory viruses are single-stranded RNA viruses that are detected by TLR3,⁷ and 8 of which neutrophils predominately express TLR8, low levels of TLR7 and little to no TLR3.⁶–⁸ We speculate that the inability of RV and influenza to replicate in

Figure 3 Matrix metalloproteinase (MMP)-9 release sub-analysis of neutrophils from asthmatic versus non-asthmatic patients following stimulation with bacterial compounds and viral surrogates. MMP-9 release from asthmatic (n = 8 (a), n = 9 (b), black bars) and non-asthmatic (n = 13, white bars) neutrophils stimulated with (a) bacterial compounds: lipopolysaccharide (LPS) (1 μg/mL), f-met-leu-phe (fMLP) (100 nM) and dimethyl sulfoxide (DMSO) (vehicle control) and (b) viral surrogates: imiquimod (3 μg/mL), R848 (1.5 μg/mL) and polyinosinic : polycytidylic acid (poly I:C) (10 μg/mL) after 1 h. (c) Representative image of a zymogram gel from one patient.

Figure 4 CXCL8 levels and degranulation products of neutrophils stimulated with RV16. (a) CXCL8, (b) neutrophil elastase (NE) and (c) matrix metalloproteinase (MMP)-9 release from pooled asthmatic and non-asthmatic neutrophils stimulated with RV16. n = 29 (a), n = 21 (b), n = 22 (c).
neutrophils could explain our results as the limited amount of viral RNA derived from the initial infection may be insufficient to activate the TLRs. Furthermore, RSV has a limited capacity to replicate within neutrophils that agrees with this explanation.21

Our study suggests that direct activation of neutrophils by virus may not be the main mechanism involved in these infections, particularly RV infections. Many respiratory viruses primarily infect the epithelium and the resulting immune response may initiate a robust neutrophilic response. Other immune cells may also be activated and could potentially cross-talk with neutrophils to activate them, which could be an area of further investigation. As live viruses, in general, had a limited capacity to activate neutrophils, we did not have the statistical power required for sub-analysis between asthmatic and non-asthmatic neutrophils stimulated with respiratory viruses. We speculate that differential responses to RSV might occur given our observation with R848.

Neutrophils are associated with a variety of lung diseases including asthma and are believed to be dysfunctional in disease states. Baines et al. demonstrated that airway neutrophils had impaired CXCL8,
IL-1β and tumour necrosis factor α release in response to LPS; however, blood neutrophils did not, albeit there was a similar trend.10 Similarly, we also found that blood neutrophils did not have impairment of the LPS response in respect to CXCL8 release. This demonstrates the potential differences between sputum and blood neutrophils. Alternatively, the differences between this and the previous study may be due to age differences between the asthmatics (35 in this study versus 59) as neutrophil function changes with age,22 or the severity of their asthma as we recruited patients who had milder asthma in comparison with the previously published study.

In this study, we were limited to the use of peripheral blood neutrophils and despite their limitation they still provide valuable insights into the pathophysiology of asthma. Neutrophils are short-lived inflammatory cells (12–24 h), and during viral infections neutrophilia occurs as a result of neutrophil migration from the blood. Therefore, we believe that studying blood neutrophils is an appropriate model to use for investigating the effects of acute viral infections.

Viral surrogates have been extensively used by our group to mimic viral infections as well as to study TLR activation.23 We demonstrated that neutrophils have the relevant receptors to become activated and release CXCL8 in the context of both bacterial and viral infections. CXCL8 is a potent chemoattractant for neutrophils which is released by a variety of cells, including neutrophils,24 which can therefore amplify recruitment in a positive feedback manner if not tightly regulated. Interestingly, CXCL8 could not be detected in supernatants 1 h post-stimulation, displaying de novo synthesis of this cytokine. All the stimulants used were able to induce CXCL8 release, albeit to varying degrees. It may be tempting to relate these differing responses to receptor expression levels but different potencies of our agonists, being full or partial agonists, or intrinsic differences in downstream signalling cascades could explain our observations; however, exploration of this mechanism was beyond the scope of this study.

Degranulation is an important effector function of neutrophils. NE and MMP-9 are two of many components found in granules and are particularly important in clearing Gram-negative bacteria and migration, respectively.25,26 All stimulants, except poly I:C, induced release of NE and MMP-9. Poly I:C also had low potency in CXCL8 release. TLR3, the receptor for poly I:C, is believed to be present in neutrophils that would partly explain our observations.7 Poly I:C may also be a ligand for other intracellular RNA receptors such as melanoma differentiation-associated protein 5 (MDA-5),27 and induction of CXCL8 may be due to MDA-5 activation rather than TLR3.

The patients in this study were predominately mild asthmatics who were regularly taking ICS. Inhaled steroid use is potentially a confounding and limiting factor of this study as steroids increase the lifespan of neutrophils by inhibiting apoptosis28 if steroids were effecting neutrophil function, it may be reasonable to assume that all outputs would be different; however, we only observed greater responses with the TLR8 agonist. As this study mainly consisted of mild asthmatics, it would be interesting to investigate if differences would be seen in neutrophils from a more severe cohort.

In conclusion, we have found that neutrophils contain the relevant components to detect and respond to both bacteria and viruses. Of importance, was our finding that TLR8 activation resulted in greater CXCL8 production from asthmatic neutrophils, which may contribute to neutrophilic inflammation in the Airways. Our data suggest that neutrophils are unlikely to be directly activated by RV during asthma exacerbations. We propose that airway epithelium or smooth muscle, both of which are known to be significantly modulated in the context of asthma,29,30 may play an important role in initiating a cascade of events during infection that results in extensive neutrophilic inflammation. Alternatively, it is not activation of neutrophils that is significant during exacerbations, rather the resolution or regulation of neutrophilic inflammation following infection that may be the determining factor in exacerbations. Animal models of lung viral infection clearly show that inhibition of lung neutrophilia causes detrimental outcomes,31–33 and defective resolution of inflammation is hypothesized to contribute to the chronicity of the disease.34 The question now posed is; are asthma exacerbations prolonged by excessive neutrophilic inflammation?

Acknowledgements

This study was funded by the National Health and Medical Research Council (NHMRC), Australia. J.K.B. was supported by a NHMRC Career Development Fellowship #1032695. B.G.O. was supported by a NHMRC Career Development Fellowship #1028880.

REFERENCES

1. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875–9.

2. Jatakanon A, Uasuf C, Maziarik W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. 2006; 172: 433–9.

3. Jarjour NN, Gern JE, Kelly EAB, Swenson CA, Dick CR, Busse WW. The effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils. J. Allergy Clin. Immunol. 2000; 105: 1169–77.

4. Berger M, Hisieh C-Y, Bakele M, Marcos V, Rieber N, Kormann M, Mays L, Hofer L, Neth O, Vítkov I et al. Neutrophils express distinct RNA receptors in a non-canonical way. J. Biol. Chem. 2012; 287: 19409–17.

5. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003; 102: 2660–9.
8 Nagase H, Okugawa S, Ota Y, Yamauchi M, Tomizawa H, Matsushima K, Ohta K, Yamamoto K, Hirai K. Expression and function of toll-like receptors in eosinophils: activation by toll-like receptor 7 ligand. *J. Immunol.* 2003; **171**: 3797–82.

9 Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PAB, Bartlett NW, Kebadze T, Mallia SV, Papi A, Johnston SL. Role of deficient type III interferon-lambda production in asthma exacerbations. *Nat. Med.* 2006; **12**: 1023–6.

10 Baines KJ, Simpson JL, Scott RJ, Gibson PG. Immune responses of airway neutrophils are impaired in asthma. *Exp. Lung Res.* 2009; **35**: 554–69.

11 Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-κB-mediated transcription. *J. Biol. Chem.* 1999; **274**: 9707–20.

12 Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. *J. Virol.* 2004; **78**: 4363–9.

13 Anders EM, Hartley CA, Reading PC, Ezekowitz RAB. Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin. *J. Gen. Virol.* 1994; **75**: 615–22.

14 Lefebvre JS, Lévesque S, Picard S, Paré G, Gravel A, Flamand L, Borgeat P. Extra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through activation of Toll-like receptor 4. *Arthritis Rheum.* 2011; **63**: 1527–33.

15 Van Dy L, De Pedro M, James P, Morgan L, Black JL, Burgess JK, Oliver BG. Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle. *Respir. Physiol. Neurobiol.* 2013; **14**: 1465–9921.

16 Moir LM, Ng HY, Poniris MH, Santa T, Burgess JK, Oliver BGG, Krymskaya VP, Black JL. Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. *Br. J. Pharmacol.* 2011; **164**: 83–92.

17 Edwards MR, Kebadze T, Johnson MW, Johnston SL. New treatment regimes for virus-induced exacerbations of asthma. *Pulm. Pharmacol. Ther.* 2006; **19**: 320–34.

18 Jarjour NN, Busse WW, Calhoun WJ. Enhanced production of oxygen radicals in nocturnal asthma. *Am. Rev. Respir. Dis.* 1992; **146**: 905–11.

19 Yanagisawa S, Koarai A, Sugiuira H, Ichikawa T, Kanda M, Tanaka R, Akamatsu K, Hirano T, Matsunaga K, Minakata Y et al. Oxidative stress augments toll-like receptor 8 mediated neutrophilic responses in healthy subjects. *Respir. Res.* 2009; **10**: 50.

20 Moller-Larsen S, Nyegaard M, Haagerup A, Vestbo J, Kruse TA, Borglum AD. Association analysis identifies TLR7 and TLR9 as novel risk genes in asthma and related disorders. *Thorax* 2008; **63**: 1064–9.

21 Halthide CP, Flanagan BF, Breaey SP, Hunt JA, Foncetta AM, McNamara PS, Howarth D, Edwards S, Smyth RL. Respiratory syncytial virus binds and undergoes transcription in neutrophils from the blood and airways of infants with severe bronchiolitis. *J. Infect. Dis.* 2011; **204**: 451–8.

22 Butcher S, Chobel H, Lord JM. Ageing and the neutrophil: no appetite for killing? *Immunology* 2000; **100**: 411–6.

23 Van Ly D, Faiz A, Jenkins C, Crossott B, Black JL, McParland B, Burgess JK. Characterising the mechanism of airway smooth muscle beta(2) adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells. *PLoS ONE* 2013; **8**: e56058.

24 Baggioni M, Clarkewig I. Interleukin-8, A chemotatic and inflammatory cytokine. *FEBS Lett.* 1992; **307**: 97–101.

25 Chua F, Laurent GJ. Neutrophil elastase: mediator of extracellular matrix destruction and accumulation. *Proc. Am. Thorac. Soc.* 2006; **3**: 424–7.

26 Bradley LM, Douglass MF, Chatterjee D, Akira S, Baaten BGG. Matrix metalloproteinase 9 mediates neutrophil migration into the airways in response to influenza virus-induced toll-like receptor signaling. *PLoS Pathog.* 2012; **8**: e1002641.

27 Tamassia N, Le Moigne V, Rossato M, Donini M, McCartney S, Calzetti F, Colonna M, Bazzoni F, Cassatella MA. Activation of an immunoregulatory and antiviral gene expression program in poly(I:C) transfected human neutrophils. *J. Immunol.* 2008; **181**: 6563–73.

28 Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils—separation of survival and activation outcomes. *J. Immunol.* 1995; **154**: 4719–25.

29 Oliver BG, Black JL. Airway smooth muscle and asthma. *Allergol. Int.* 2006; **55**: 215–23.

30 Holgate ST. The airway epithelium is central to the pathogenesis of asthma. *Allergol. Int.* 2008; **57**: 1–10.

31 Tate MD, Deng Y-M, Jones JE, Anderson GP, Brooks AG, Reading PC. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. *J. Immunol.* 2009; **183**: 7441–50.

32 Fujisawa H. Neutrophils play an essential role in cooperation with antibody in both protection against and recovery from pulmonary infection with influenza virus in mice. *J. Virol.* 2008; **82**: 2772–83.

33 Tumpey TM, García-Sastre A, Taubenberger JK, Palese P, Swanye DE, Pantin-Jackwood MJ, Schultz-Cherry S, Solórzano A, Van Rooljen N, Katz JM et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. *J. Virol.* 2005; **79**: 14933–44.

34 Levy BD, Vachier I, Serhan CN. Resolution of inflammation in asthma. *Clin. Chest Med.* 2012; **33**: 559–70.

Supplementary Information

Additional Supplementary Information can be accessed via the html version of this article at the publisher’s website.

Figure S1 Detection of RV16 RNA by reverse transcription (RT)-PCR in neutrophil pellets 24 h post-stimulation with RV16 (MOI1).

Figure S2 Detection of RSV RNA by reverse transcription (RT)-PCR in neutrophil pellets 24 h post-stimulation with RSV (MOI1).

Appendix S1 Methods.